2-Apr-2026
Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags
Seeking Alpha News (Wed, 1-Apr 12:15 PM ET)
Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus
Seeking Alpha News (Sun, 29-Mar 9:05 AM ET)
PRNewswire (Wed, 18-Mar 3:00 PM ET)
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
PRNewswire (Tue, 17-Mar 8:00 AM ET)
Globe Newswire (Tue, 17-Mar 7:00 AM ET)
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
PRNewswire (Tue, 24-Feb 2:00 PM ET)
DaVita’s Strategic Investment in Elara Caring Aims to Transform Home-Based Kidney Care
Market Chameleon (Tue, 3-Feb 5:28 AM ET)
DaVita’s 2025 Results Highlight Strong Adjusted Earnings Amid Share Buybacks and Margin Stability
Market Chameleon (Tue, 3-Feb 2:09 AM ET)
DaVita Inc. 4th Quarter 2025 Results
PRNewswire (Mon, 2-Feb 4:05 PM ET)
Elara Caring Secures New Strategic Investment from Ares and DaVita
Business Wire (Mon, 2-Feb 3:00 PM ET)
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Davita trades on the NYSE stock market under the symbol DVA.
As of April 2, 2026, DVA stock price declined to $145.58 with 1,028,525 million shares trading.
DVA has a beta of 0.20, meaning it tends to be less sensitive to market movements. DVA has a correlation of 0.01 to the broad based SPY ETF.
DVA has a market cap of $9.73 billion. This is considered a Mid Cap stock.
Last quarter Davita reported $4 billion in Revenue and $3.40 earnings per share. This beat revenue expectation by $104 million and exceeded earnings estimates by $.19.
In the last 3 years, DVA traded as high as $179.60 and as low as $71.51.
The top ETF exchange traded funds that DVA belongs to (by Net Assets): VTI, RSP, VOO, VB, VBR.
DVA has underperformed the market in the last year with a price return of -4.2% while the SPY ETF gained +18.2%. However, in the short term, DVA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +28.1% vs -3.6% return in SPY. But in the last 2 weeks, DVA shares have been beat by the market, returning -2.2% compared to an SPY return of -0.6%.
DVA support price is $147.54 and resistance is $153.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVA shares will trade within this expected range on the day.